Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
NCI-CCC Breast Tumor Board Question
•
Radiology
•
Imaging
In which clinical settings do you use the Cerianna (fluoroestradiol F18) PET scan for breast cancer?
Related Questions
How do you council patients diagnosed with hormone receptor-positive breast cancer currently or interested in taking exogenous hormones (e.g. testosterone) for gender-affirming treatment?
Would you offer adjuvant abemaciclib plus endocrine therapy for favorable histology ER+/PR+/HER2-negative tumors such as pure tubular, mucinous, cribriform, or papillary that otherwise meet MonarchE trial criteria?
How would you manage a male patient who has a germline BRCA2 mutation with node-positive, HR-positive invasive ductal carcinoma who is unable/unwilling to receive tamoxifen or AI + goserelin?
For patients with metastatic HER2-null (IHC 0+) breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?
Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?
In patients with localized triple-negative breast cancer and residual disease at time of surgery following neoadjuvant KEYNOTE-522 regimen, when would you recommend adding adjuvant capecitabine or another agent to pembrolizumab?
How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?
Do you approach treatment any differently for a patient with prior early-stage hormone receptor positive breast cancer who experiences metastatic triple negative recurrence?
In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?
In which situations do you consider post-mastectomy radiation therapy when the patient has a localized node-positive breast cancer with a complete nodal response and minimal residual disease in the breast post-neoadjuvant chemotherapy?